Australia's largest stock trading and investment forum Australia's #1 stock forum

NEU

Click for more information

4.33%

$13.59 neuren pharmaceuticals limited

Ann: 2023 Annual Report to shareholders, page-168

First 168 Last

Share
Profile

Follow
Flash99

727 Posts.

167

28/04/24

16:30

Post #: 73544838
Share

Originally posted by hottod: ↑

Yes, Opthea’s pivotal trials are very large, but they were never going to be in ~100 patients, such as can be found in some rare disease trials.

Opthea's Phase 3 trails are testing sozinibercept in combination with the two leading wet AMD therapies, Lucentis and Eylea.

A comparison with patient numbers in the Phase 3 trials used for the approval of these two drugs shows that Lucentis was assessed in three trials with a total of 1,323 patients and Eylea in two trials with a total of 2,412 patients.

Additionally. Opthea’s pivotal trials are more complex that those conducted for Lucentis and Eylea in wet AMD. Opthea is not only testing its drug in combination with two different drugs in two different trials, it’s also assessing two different dosing regimens; thus 3 arms are required in each trial.

Each trial has 990 patients, with 330 in each arm. The trials are designed for ~90% power and 5% type 1 error rate.

Can’t help beyond that as my knowledge and understanding of clinical trial design and statistics is very basic – perhaps someone with more knowledge might be able to help on the OPT forum?

Expand

Thanks hottod. Knowledgeable as always. Happy to leave the trial design over there in the past as I'm sure it was discussed at length back then.

NEU Price at posting: $18.65 Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

DRO

Droneshield shares move up on $13.5M US govt contract

EXR

Elixir winds up QLD operations with five of six zones flowing gas – but shares plummet -50%

WAF

West African Res jumps on claim mine safe under Burkina Faso's junta; HotCopper ponders Russia

TMK

TMK Energy kicks off drilling for new pilot wells in Mongolia's vastly underexplored Gobi

LMS

Litchfield boosts its copper, base and precious metals footprint in the NT with acquisitions

There are more pages in this discussion • 27 more messages in this thread...

First 168 Last

Add NEU (ASX) to my watchlist

(20min delay)
Last $13.59		Change -0.615(4.33%)		Mkt cap ! $1.710B

Open	High	Low	Value	Volume
$13.88	$13.91	$13.29	$9.230M	683.5K

Buyers (Bids)

No.	Vol.	Price($)
14	514	$13.58

Sellers (Offers)

Price($)	Vol.	No.
$13.60	265	6

View Market Depth

No.	Vol.	Price($)
3	172	13.630
9	664	13.620
5	901	13.610
7	1042	13.600
5	753	13.590

Price($)	Vol.	No.
13.640	227	3
13.650	1409	3
13.660	1761	5
13.670	600	4
13.680	609	4

Last trade - 14.43pm 08/10/2024 (20 minute delay)

NEU (ASX) Chart